M&A Deal Summary

Novartis Acquires The Medicines Company

On November 24, 2019, Novartis acquired life science company The Medicines Company for 9.7B USD

Acquisition Highlights
  • This is Novartis’ 17th transaction in the Life Science sector.
  • This is Novartis’ largest (disclosed) transaction.
  • This is Novartis’ 17th transaction in the United States.
  • This is Novartis’ 1st transaction in New Jersey.

M&A Deal Summary
Date 2019-11-24
Target The Medicines Company
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition
Deal Value 9.7B USD
Advisor(s) Goldman Sachs
J.P. Morgan Securities (Financial)
Paul, Weiss, Rifkind, Wharton & Garrison (Legal)

Target

The Medicines Company

Parsippany, New Jersey, United States
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.
The Medicines Company is a provider of solutions in acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The Medicines Company was formed in 1996 and is based in Parsippany, New Jersey. The Medicines was founded in 1996 and is based in Parsippany, New Jersey.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 46.7B USD (2023)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 21 of 32
Sector (Life Science) 17 of 26
Type (Add-on Acquisition) 17 of 28
State (New Jersey) 1 of 1
Country (United States) 17 of 24
Year (2019) 3 of 3
Size (of disclosed) 1 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-16 Novartis AG - TOBRADEX & NATACYN

Basel, Switzerland

Novartis AG's TOBRADEX is a fixed-dose topical antibiotic and corticosteroid combination indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Novartis AG's NATACYN is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-20 Amblyotech

United States

Amblyotech, Inc. is a digital therapeutics software company, which develops active and passive video therapies to treat amblyopia ("lazy eye"), a debilitating ocular condition that affects 3% of the global population and is a leading cause of monocular blindness. Amblyotech was founded in 2013 and is based in United States.

Buy -
Mergr

Product

Company

Legal